QUEBEC CITY, Dec. 22, 2014 /CNW Telbec/ - Opsens Inc.
("Opsens") (TSXV: OPS) is pleased to announce the first use of
its Fractional Flow Reserve ("FFR") products in several patients
during the 21st Kamakura Live Demonstration Course 2014
(www.kamakuralive.net) in Yokohama
(Japan) by Dr. Shigeru Saito. The OptoWire and OptoMonitor are
Opsens' products for FFR measurements to optimize the diagnosis and
guide the therapy in patients with coronary artery disease.
"The Kamakura Live Demonstration Course is an
event to introduce to Japanese cardiologists new medical devices
and practices intended to improve the treatment and the health of
patients. Opsens' FFR products fit very well with this vision given
the important benefits that they provide for efficiency and
effectiveness in the treatment of coronary lesions. It was a great
experience for me to demonstrate this new FFR system and I intend
to continue using it", said Dr. Saito.
"Opsens' team is honoured to have their products
used by Dr. Saito in the prestigious Kamakura Live Demonstration
Course. The credibility of Dr. Saito and this event will be an
asset to our marketing activities in Japan as well as around the world. Opsens is
also pleased to announce that we have obtained a new regulatory
approval in Japan for the latest
generation of OptoWire. With this new generation FFR wire, we are
now initiating our limited market launch with selected hospitals in
Japan", said Louis Laflamme, President and CEO of Opsens.
Opsens aims at becoming a key player in the
guidewire FFR market with the OptoWire, a nitinol-based optical
guidewire for FFR. The OptoWire provides intra-coronary blood
pressure measurements with unique, patented optical pressure
guidewire technologies. It is immune to adverse effects related to
blood contact, and allows easy and reliable connectivity that leads
to reliable FFR measurements in extended conditions of usage. The
OptoWire is also designed to provide cardiologists with a guidewire
delivering optimized performances to navigate coronary arteries and
reach blockages with ease. Based on industry sources, the FFR
market represented over US$250
million in sales in 2013 and is expected to reach
US$1 billion in the medium-term.
Opsens is confident that it is well positioned to capitalize on
this significant growth opportunity.
About Opsens Inc. (www.opsensmedical.com
or www.opsens.com)
The Company focuses mainly on two large and
growing markets: the interventional cardiology and the oil and gas
industry. In interventional cardiology, Opsens offers advanced
optical based pressure guidewire that aims at improving the
clinical outcome of patients with coronary artery disease. Opsens
also develops, manufactures and installs innovative fibre optic
sensing solutions for critical applications such as the monitoring
of oil wells and other demanding industrial applications.
Forward-looking statements contained in this
press release involve known and unknown risks, uncertainties and
other factors that may cause actual results, performance and
achievements of Opsens to be materially different from any future
results, performance or achievements expressed or implied by the
said forward-looking statements.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE OPSENS INC.